Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.
01 Dezembro 2020 - 1:30PM
Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with cancer, has announced the change of
its corporate name to Panbela Therapeutics, Inc. effective December
2, 2020. The Company’s trading symbol will also change from SNBP to
PBLA at the opening of the markets on December 2, 2020. As a result
of the change, the CUSIP number for the company’s common stock will
also change to 69833Q100. Stockholders are not required to exchange
their existing share certificates or warrants for new certificates
or warrants bearing the new name. The name change does not affect
the company’s capital structure or the rights of the company’s
stockholders, and no action is required by existing stockholders.
About SBP-101 SBP-101 is a proprietary
polyamine analogue designed to induce polyamine metabolic
inhibition (PMI) by exploiting an observed high affinity of the
compound for pancreatic ductal adenocarcinoma. The molecule has
shown signals of tumor growth inhibition in clinical studies of US
and Australian metastatic pancreatic cancer patients, suggesting
complementary activity with an existing FDA-approved chemotherapy
regimen. In clinical studies to date, SBP-101 has not shown
exacerbation of the typical chemotherapy-related adverse events of
bone marrow suppression and peripheral neuropathy. The safety data
and PMI profile observed in the company’s current clinical trial
provides support for continued evaluation of the compound in a
randomized clinical trial. For more information, please visit
https://clinicaltrials.gov/ct2/show/NCT03412799 .
About Panbela
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing disruptive therapeutics for patients with urgent
unmet medical needs. The company’s initial product candidate,
SBP-101, is for the treatment of patients with metastatic
pancreatic ductal adenocarcinoma, the most common type of
pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to
treating patients with pancreatic cancer and exploring SBP-101’s
potential for efficacy in combination with other agents and in
treating other types of cancer. Further information can be found at
www.sunbiopharma.com and as of December 2, 2020 at www.panbela.com
. Panbela’s common stock will remain listed on The Nasdaq Stock
Market LLC and has been approved to commence trading under the
symbol PBLA on December 2, 2020.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains “forward-looking statements,”
including within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
words such as: “believes,” “dedicated,” “expects,” “intends,”
“may,” “milestone,” or “plans.” Examples of
forward-looking statements include, among others, statements we
make regarding, potential effects of FDA Fast Track designation,
future determinations of the characteristics of SBP-101 and its
effectiveness, uses of proceeds from recent financings.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only
on our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially and adversely from the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: (i) our ability to obtain
additional funding to complete Phase 1 clinical trial; (ii)
progress and success of our Phase 1 clinical trial; (iii) the
impact of the current COVID-19 pandemic on our ability to complete
enrollment in our current clinical trial; (iv) our ability to
demonstrate the safety and effectiveness of our SBP-101 product
candidate (v) our ability to obtain regulatory approvals for our
SBP-101 product candidate in the United States, the European Union
or other international markets; (vi) the market acceptance and
level of future sales of our SBP-101 product candidate; (vii) the
cost and delays in product development that may result from changes
in regulatory oversight applicable to our SBP-101 product
candidate; (viii) the rate of progress in establishing
reimbursement arrangements with third-party payors; (ix) the effect
of competing technological and market developments; (x) the costs
involved in filing and prosecuting patent applications and
enforcing or defending patent claims; and (xi) such other factors
as discussed in Part I, Item 1A under the caption “Risk Factors” in
our most recent Annual Report on Form 10-K, any additional risks
presented in our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Any forward-looking statement made by us in
this press release is based on information currently available to
us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement or
reasons why actual results would differ from those anticipated in
any such forward-looking statement, whether written or oral,
whether as a result of new information, future developments or
otherwise .
Contact Information:
Investors:
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com
Media:
Tammy Groene
Panbela Therapeutics, Inc.
(952) 479-1196
IR@sunbiopharma.com (through December 1, 2020)
IR@panbela.com (as of December 2, 2020)
Sun BioPharma (NASDAQ:SNBP)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sun BioPharma (NASDAQ:SNBP)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024